ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 402006

Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.

Biddison WE and 1 other. Proc Natl Acad Sci U S A, 1977. Cited by 49 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Papers, record 402006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/402006

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.
PubMed
Journal
Proc Natl Acad Sci U S A
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
1.08
iCite
Revised in PubMed
2019-05-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Biddison WEW E
2Palmer JCJ C

Source PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, NeoplasmMajor topic
Immunity, CellularMajor topic
Mast-Cell SarcomaMajor topic
Animals
Ascites
Ascitic Fluid
Cytotoxicity Tests, Immunologic
Female
Histocompatibility Antigens
Mice
Mice, Inbred Strains
Neoplasm Transplantation
Neoplasms, Experimental
Receptors, Antigen, B-Cell
Time Factors
Transplantation, Homologous

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114,069,836ANTIGENIC PROPERTIES OF EXPERIMENTAL LEUKEMIAS. I. SEROLOGICAL STUDIES IN VITRO WITH SPONTANEOUS AND RADIATION-INDUCED LEUKEMIAS.J Natl Cancer Inst1963https://conductscience.org/library/papers/14069836PubMed
25,672,552Serologic approaches to the study of cancer in animals and in man.Cancer Res1968https://conductscience.org/library/papers/5672552PubMed
34,140,238Effect of antigen density on complement-mediated lysis, T-cell-mediated killing, and antigenic modulation.J Natl Cancer Inst1974https://conductscience.org/library/papers/4140238PubMed
44,151,339Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.Adv Immunol1974https://conductscience.org/library/papers/4151339PubMed
54,372,543Antigenic inhibition of cell-mediated cytotoxicity against tumour cells.Nature1974https://conductscience.org/library/papers/4372543PubMed
64,208,919Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells.J Immunol1974https://conductscience.org/library/papers/4208919PubMed
74,610,077Antigenic modulation in vitro. I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes.J Exp Med1974https://conductscience.org/library/papers/4610077PubMed
84,604,193Cell-mediated immunity to tumor cells.Adv Cancer Res1974https://conductscience.org/library/papers/4604193PubMed
94,598,016Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.J Exp Med1974https://conductscience.org/library/papers/4598016PubMed
104,597,622Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.Adv Immunol1974https://conductscience.org/library/papers/4597622PubMed

1 to 10 of 25

See all 25 references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
21,626,415Immunosuppressive tumor microenvironment in cervical cancer patients.Cancer Microenviron2011https://conductscience.org/library/papers/21626415PubMed
18,188,562Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer.Cancer Immunol Immunother2008https://conductscience.org/library/papers/18188562PubMed
7,333,657Variation of expression of histocompatibility antigens on tumor cells: absence of H-2Kk-gene products from a gross-virus-induced leukemia in BALB.K.Immunogenetics1981https://conductscience.org/library/papers/7333657PubMed
6,985,248Antigenic variation in cancer metastasis: immune escape versus immune control.Cancer Metastasis Rev1982https://conductscience.org/library/papers/6985248PubMed
6,776,227Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.J Exp Med1980https://conductscience.org/library/papers/6776227PubMed
6,424,695Proliferative patterns of lymphocytes in lymph nodes during tumour development: involvement of T and B cell areas.Br J Cancer1984https://conductscience.org/library/papers/6424695PubMed
6,187,879Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.J Exp Med1983https://conductscience.org/library/papers/6187879PubMed
3,156,088Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.Immunology1985https://conductscience.org/library/papers/3156088PubMed
650,156
Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.
J Exp Med1978https://conductscience.org/library/papers/650156PubMed
429,962The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.J Exp Med1979https://conductscience.org/library/papers/429962PubMed

1 to 10 of 11

See all 11 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/402006

GET https://conductscience.org/api/papers/v1/402006/references?page=2

API referenceFor AI assistants